Harvard Bioscience, Inc. (HBIO) Misses Q4 EPS by 2c

Harvard Bioscience, Inc. (NASDAQ: HBIO) reported Q4 EPS of $0.02, $0.02 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $28.2 million versus the consensus estimate of $29.2 million.

For earnings history and earnings-related data on Harvard Bioscience, Inc. (HBIO) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Royal Unibrew reports higher interim first-half profit as margins improve
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance